-
Takeda’s Exkivity Receives First Prescription in China with Innovative Payment Solutions
•
Takeda Pharmaceutical Co., Ltd has announced the first prescription of its lung cancer therapy Exkivity (mobocertinib) in China. The Japanese pharmaceutical giant will partner with China-based health platform MediTrust Health to launch innovative payment solutions for the drug in China, making this advanced therapy more accessible to patients. Clinical Need…
-
Pudong New Area Grants Duty-Free Import Qualifications to Seven Companies
•
Seven companies have been awarded scientific and technological innovation duty-free import qualification designations by the foreign R&D center in Pudong New Area. Among the awardees are Fosun Kite Biotechnology Co., Ltd, a joint venture (JV) between Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) and Gilead subsidiary Kite Pharma, as…
-
Harbour BioMed’s Batoclimab Shows Positive Results in gMG Phase III Trial
•
Harbour BioMed (HKG: 2142), a biotech company operating out of the United States, the Netherlands, and Suzhou (China), has announced positive topline results from its phase III clinical trial of batoclimab (HBM9161) for the treatment of generalized myasthenia gravis (gMG). The pivotal clinical study, designed to confirm the efficacy and…
-
BGI Group Subsidiaries Added to US Trade Blacklist by Commerce Department
•
The US Department of Commerce (DOC)’s Bureau of Industry and Security (BIS) has added 37 companies from various countries and industries to its trade blacklist, including 28 Chinese entities. Among the China-based companies are three subsidiaries of genomics giant BGI Group: BGI Research, BGI Tech Solutions (Hongkong) Co., Ltd, and…
-
Sanyou Biopharmaceuticals Expands Global Reach with New Cambridge Office
•
Sanyou Biopharmaceuticals, a leading provider of biotech CRDMO services, is set to open a new office in the Cambridge Innovation Centre (CIC) on March 2, 2023. This strategic move marks a significant step forward in expanding the company’s global footprint and enhancing its capabilities to serve and collaborate with biotechs…
-
Sanofi’s Dupixent Receives Priority Review for Prurigo Nodosa Treatment
•
French pharmaceutical major Sanofi (NASDAQ: SNY) has announced that it has received priority review status from the Center for Drug Evaluation (CDE) for its Dupixent (dupilumab) to treat prurigo nodosa (PN) in adults. This marks another significant breakthrough in the type 2 inflammation field, following the drug’s indication approval for…
-
China’s Premier Li Keqiang Highlights Economic and Social Advances in Annual Report
•
Premier Li Keqiang delivered his annual Government Work Report at the “Two Sessions” meeting, which includes the National People’s Congress and commenced this week in Beijing. The report highlighted significant economic and social advancements, reflecting the government’s efforts in various sectors. Economic HighlightsDuring 2022, China’s national GDP reached RMB 121…
-
Eli Lilly’s Retevmo Launched in China by Innovent Biologics
•
Eli Lilly & Co’s (NYSE: LLY) Retevmo (selpercatinib) has been officially launched in the Chinese market. The drug is being commercialized by domestic firm Innovent Biologics Inc. (HKEX: 01801) under a partnership deal signed between the two companies in March last year. This collaboration aims to bring innovative treatments to…
